Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Assessment of alpha- and beta-adrenoceptor blocking actions of labetalol.

Literature DB >> 9968

Assessment of alpha- and beta-adrenoceptor blocking actions of labetalol.

Abstract

Isoprenaline dose-response curves plotting increases in heart rate before and after labetalol are suggestive of competitive antagonism at beta-adrenoceptor sites. Phenylephrine dose-response curves using increases in systolic pressure before and after labetalol are suggestive of competitive antagonism at alpha-adrenoceptor sites. The ratio of alpha:beta-adrenoceptor antagonism induced by labetalol is approximately 1:3. Peak pharmacological responses after a single oral dose of labetalol (400 mg) occurred between 90-120 min after administration.

Entities: Chemical

Mesh：

Substances：

Year: 1976 PMID： 9968 PMCID： PMC1428931 DOI： 10.1111/j.1365-2125.1976.tb00637.x

Source DB: PubMed Journal: Br J Clin Pharmacol ISSN： 0306-5251 Impact factor: 4.335

13 in total

1. A SPHYGMOMANOMETER FOR EPIDEMIOLOGISTS.

Authors: G A ROSE; W W HOLLAND; E A CROWLEY
Journal: Lancet Date: 1964-02-08 Impact factor: 79.321

2. Circulatory effects of sympathomimetic amines.

Authors: J W ECKSTEIN; F M ABBOUD
Journal: Am Heart J Date: 1962-01 Impact factor: 4.749

3. Clinical pharmacology of a beta-adrenergic-blocking agent (Nethalide).

Authors: A C DORNHORST; B F ROBINSON
Journal: Lancet Date: 1962-08-18 Impact factor: 79.321

4. Antihypertensive beta blocking action as related to renin and age: a pharmacologic tool to identify pathogenetic mechanisms in essential hypertension.

Authors: F R Bühler; F Burkart; B E Lütold; M Küng; G Marbet; M Pfisterer
Journal: Am J Cardiol Date: 1975-10-31 Impact factor: 2.778

5. Preliminary studies of the pharmacological effects of 5-[1-hydroxy-2-((1-methyl-3-phenylpropyl)amino)-ethyl] salicylamide (AH 5158) in man.

Authors: A J Boakes; E J Knight; B N Prichard
Journal: Clin Sci Date: 1971-04 Impact factor: 6.124

6. Clinical investigation of an antagonist at alpha- and beta-adrenoceptors-AH5158A.

Authors: J G Collier; N A Dawnay; C Nachev; B F Robinson
Journal: Br J Pharmacol Date: 1972-02 Impact factor: 8.739

7. Combined alpha- and beta-adrenoceptor blocking drug AH 5158: further studies on alpha-adrenoceptor blockade in anaesthetized animals.

Authors: I Kennedy; G P Levy
Journal: Br J Pharmacol Date: 1975-04 Impact factor: 8.739

8. Pharmacology of AH 5158; a drug which blocks both - and -adrenoceptors.

Authors: J B Farmer; I Kennedy; G P Levy; R J Marshall
Journal: Br J Pharmacol Date: 1972-08 Impact factor: 8.739

9. Beta-adrenoceptors in the human dorsal hand vein, and the effects of propranolol and practolol on venous sensitivity to noradrenaline.

Authors: C B White; B P Udwadia
Journal: Br J Clin Pharmacol Date: 1975-04 Impact factor: 4.335

10. Adrenoceptors and adenyl cyclase in gills.

Authors: A W Cuthbert; P Pic
Journal: Br J Pharmacol Date: 1973-09 Impact factor: 8.739

24 in total

Review 1. Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia.

Authors: W H Frishman
Journal: Cardiovasc Drugs Ther Date: 1988-09 Impact factor: 3.727

Assessment of alpha- and beta-adrenoceptor blocking actions of labetalol.

1. A SPHYGMOMANOMETER FOR EPIDEMIOLOGISTS.

2. Circulatory effects of sympathomimetic amines.

3. Clinical pharmacology of a beta-adrenergic-blocking agent (Nethalide).

4. Antihypertensive beta blocking action as related to renin and age: a pharmacologic tool to identify pathogenetic mechanisms in essential hypertension.

5. Preliminary studies of the pharmacological effects of 5-[1-hydroxy-2-((1-methyl-3-phenylpropyl)amino)-ethyl] salicylamide (AH 5158) in man.

6. Clinical investigation of an antagonist at alpha- and beta-adrenoceptors-AH5158A.

7. Combined alpha- and beta-adrenoceptor blocking drug AH 5158: further studies on alpha-adrenoceptor blockade in anaesthetized animals.

8. Pharmacology of AH 5158; a drug which blocks both - and -adrenoceptors.

9. Beta-adrenoceptors in the human dorsal hand vein, and the effects of propranolol and practolol on venous sensitivity to noradrenaline.

10. Adrenoceptors and adenyl cyclase in gills.

Review 1. Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia.

2. Circulatory and alpha-adrenoceptor blocking effects of phentolamine.

3. Effects of labetalol and propranolol on histamine-induced bronchoconstriction in normal subjects.

4. Tilisolol hydrochloride dilates coronary arteries through an ATP-sensitive K(+)-channel opening mechanism in dogs.

Review 5. Labetalol: a review of its pharmacology and therapeutic use in hypertension.

6. Improved deep controlled hypotension in aneurysmal surgery.

7. Propranolol vs metoprolol vs labetalol: a comparative study in essential hypertension.

8. Comparison of medroxalol and labetalol, drugs with combined alpha- and beta-adrenoceptor antagonist properties.

9. Alternatives to beta-blockade in therapy of hypertension with angina pectoris: role of nifedipine or of labetalol.

10. Elimination kinetics of labetalol in severe renal failure.